Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia

  • J Cardiovasc Dev Dis. 2022 Jan 25;9(2):42. doi: 10.3390/jcdd9020042.
Ioannis Parthymos  1 ,  Michael S Kostapanos  2 ,  George Liamis  1 ,  Matilda Florentin  1
Affiliations
  • 1. Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.
  • 2. Lipid Clinic, Department of General Medicine, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
PMID: 35200696 DOI: 10.3390/jcdd9020042
Abstract

Hypertriglyceridemia has been identified as a risk factor for Cardiovascular Disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel Apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.

Keywords
apolipoprotein C-III; fibroblast growth 21 factor; lipoprotein lipase; triglycerides; volanesorsen; ω-3 fatty acids.
Products